Levomilnacipran
Total Payments
$146,948
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $146,948 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $146,948 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Levomilnacipran Fasted Pivotal Study | West-Ward Pharmaceuticals | $74,652 | 0 |
| Levomilnacipran Fasted Pilot Study | West-Ward Pharmaceuticals | $31,392 | 0 |
| Levomilnacipran Fed Pivotal Study | West-Ward Pharmaceuticals | $24,152 | 0 |
| Levomilnacipran Fed Pilot Study | West-Ward Pharmaceuticals | $16,752 | 0 |
Top Doctors Receiving Payments for Levomilnacipran
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | — | $146,948 | 4 |
Ad
Manufacturing Companies
- West-Ward Pharmaceuticals $146,948
Product Information
- Type Drug
- Total Payments $146,948
- Total Doctors 0
- Transactions 4
About Levomilnacipran
Levomilnacipran is a drug associated with $146,948 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is West-Ward Pharmaceuticals.
Payment data is available from 2017 to 2017. In 2017, $146,948 was paid across 4 transactions to 0 doctors.
The most common payment nature for Levomilnacipran is "Unspecified" ($146,948, 100.0% of total).
Levomilnacipran is associated with 4 research studies, including "Levomilnacipran Fasted Pivotal Study" ($74,652).